Stoke Therapeutics Grants Options for 245,920 Shares to 18 New Employees

• Stoke Therapeutics granted newly appointed Senior Vice President, Chief Information Officer Stephen Aschettino stock options to purchase 70,000 common shares.
• Seventeen other new employees received stock options covering 175,920 common shares. All grants took effect October 15, 2026.
• The options carry an exercise price of $24.61 per share, with 10-year terms under the 2023 Inducement Plan.
• Vesting spans four years, with 25% vesting on the first anniversary of the applicable vesting commencement date.
• The remaining shares vest monthly at 1/48 of each award over 36 months. All vesting requires continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610161620BIZWIRE_USPR_____20261016_BW401922) on October 16, 2026, and is solely responsible for the information contained therein.